[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
作者信息
Rexer H, Bedke J
机构信息
MeckEvidence, Geschäftsstelle der AUO, Seestr. 11, 17252, Schwarz, Deutschland.
Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V., Kuno-Fischer-Str. 8, 14057 Berlin, Deutschland.
出版信息
Urologe A. 2017 Mar;56(3):385-386. doi: 10.1007/s00120-017-0335-2.
PMID:28246756
Abstract
摘要
Zotero 插件